The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11071 malaria professionals are enjoying the free benefits of MalariaWorld today

monoclonal antibodies

NOT Open Access |Monoclonal antibodies show promise in phase I malaria trial

September 14, 2021 - 09:15 -- NOT Open Access
Mullard A
Nat Rev Drug Discov. 2021 Sep 6

The US National Institute of Allergy and Infectious Diseases hopes that a monoclonal antibody may provide a means of reducing the impact of malaria.

Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes

August 17, 2021 - 15:08 -- Open Access
de Jong RM, Meerstein-Kessel L, Da DF, Nsango S, Challenger JD, van de Vegte-Bolmer M, van Gemert GJ, Duarte E, Teyssier N, Sauerwein RW, Churcher TS, Dabire RK, Morlais I, Locke E, Huynen MA, Bousema T, Jore MM
NPJ Vaccines. 2021 Aug 12;6(1):101

Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage parasites during a blood meal and subsequent formation of oocysts on the mosquito midgut wall. Transmission-blocking vaccines (TBVs) and monoclonal antibodies (mAbs) target sexual stage antigens to interrupt human-to-mosquito transmission and may form important tools for malaria elimination.

Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein

March 23, 2020 - 11:30 -- Open Access
Rama Raghunandan, Bryan T. Mayer, Fidel Zavala, et al.
Malaria Journal 2020 19:113, 17 March 2020

New strategies are needed to reduce the incidence of malaria, and promising approaches include the development of vaccines and monoclonal antibodies (mAbs) that target the circumsporozoite protein (CSP). To select the best candidates and speed development, it is essential to standardize preclinical assays to measure the potency of such interventions in animal models.

Subscribe to RSS - monoclonal antibodies